Literature DB >> 18603855

[Retroperitoneal fibrosis and Castleman disease in two patients with high IgG4 levels].

Ichita Miwa1, Yasuhiko Maruyama, Masanobu Kageoka, Ken Nagata, Akihiko Ohata, Yuji Noda, Kentarou Ikeya, Tomofumi Matsui, Kenji Koda, Fumitoshi Watanabe.   

Abstract

With the cumulative increase in the number of autoimmune pancreatitis cases, the disease is now widely accepted as a symptom of IgG4-related systemic disease. We recently experienced two cases of retroperitoneal fibrosis and Castleman disease presenting high IgG4 levels without evident pancreatic lesions. Both patients were successfully treated with steroid therapy. It is necessary to acknowledge that retroperitoneal fibrosis and Castleman disease, with or without pancreatic lesions, may have aspects of IgG4-related systemic disease and that the measurement of serum IgG4 and tissue immunostaining for IgG4 should be considered for diagnosing and treating the conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18603855

Source DB:  PubMed          Journal:  Nihon Shokakibyo Gakkai Zasshi        ISSN: 0446-6586


  3 in total

1.  Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.

Authors:  Xia Zhang; Panpan Zhang; Linyi Peng; Yunyun Fei; Wei Zhang; Ruie Feng; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-06-14       Impact factor: 2.980

2.  Relationship between chronic sclerosing dacryoadenitis with high level of IgG4 and Castleman disease.

Authors:  Toshiyuki Oshitari; Jiro Yotsukura; Kaoru Asahagi; Takayuki Baba; Takashi Kishimoto; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2010-12-30

3.  Tocilizumab-effective multicentric Castleman's disease with infiltration of eosinophil and IgG4-positive plasma cells: A case report.

Authors:  Yusuke Katsumata; Jun Ikari; Nozomi Tanaka; Mitsuhiro Abe; Kenji Tsushima; Yoko Yonemori; Koichiro Tatsumi
Journal:  Respir Med Case Rep       Date:  2018-06-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.